Introduction
Infantile hemangioma (IH) is a common tumor composed of disorganized blood vessels and immature cells [1, 2] . It has an incidence 5-7% in newborns of European descent; the prevalence is higher in females and in premature, low birth weight infants [3] . Although a benign and usually harmless, some IHs cause deformation and destruction of facial features, and obstruction of vision and breathing. Many tumors result in permanent cutaneous residua, which can be disfiguring. The tumor has three distinctive clinical and histological phases. The proliferating phase is characterized by undeveloped blood channels interspersed with immature, proliferating cells. Transition to the involuting phase represents vascular differentiation; nascent channels develop into well-formed endothelial-lined and pericyteinvested blood vessels. In the final involuted phase, the tumor is replaced with fibro-fatty tissue with scattered capillaries and large draining vessels. The spontaneous regression of blood vessels is the defining feature of IH.
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In sum, hemangioma-genesis represents human vascular differentiation, followed by vascular regression and adipogenesis.
Hemangioma-derived stem cells (HemSCs) are multipotential cells isolated from specimens of human proliferating IH [4] . HemSCs exhibit a mesenchymal morphology and robust proliferation when cultured in vitro. In contrast to endothelial cells (ECs) and endothelial progenitor cells isolated from IH, HemSCs form human blood vessels with the immunophenotype and dynamics of IH when injected subcutaneously into nude mice [4] . Thus, HemSCs are the putative progenitors of IH.
Recently we showed that corticosteroids, the traditional first-line therapy for IH, inhibit the ability of HemSCs to form blood vessels in vivo by suppressing VEGF-A production by HemSCs. There was no effect on the secretion of VEGF-A from hemangioma-derived ECs or normal human cord blood-derived endothelial progenitor cells (cbEPCs) [5] . A human angiogenesis antibody array enabled us to detect the expression of 43 different pro-angiogenic cytokines, and we identified four additional cytokines that are down-regulated by corticosteroids: uPAR, MCP-1, IL-6 and matrix metalloproteinase-1 (MMP-1). A common feature of these cytokines is regulation by NF-jB [6] [7] [8] [9] [10] .
The NF-jB family of transcription factors is known to regulate the expression of multiple genes involved in immune and stress responses, inflammation, cell proliferation and cell survival. Constitutive activation of NF-jB is associated with diseases of chronic inflammation and immune dysfunction as well as cancer [11, 12] . NF-B plays a complex role in angiogenesis. Although its activity was shown to be critical for maintaining endothelial cell survival [13] [14] [15] , activation of NF-jB in endothelial cells induces expression of both angiogenic and angiostatic factors [16, 17] . Endothelial repression of NF-jB has been shown to increase the size and vascularity of tumor metastases [18] .
The role of NF-jB in the pathogenesis of IH and in the tumor's response to corticosteroids is unknown. In the current work, we tested the expression levels several NF-jB targets in proliferating versus involuting IH. We also investigated the effect of corticosteroids on NF-jB activity in HemSCs. Finally, we tested the effect of NF-jB inhibition on the secretion of pro-angiogenic factors by HemSCs, and in particular VEGF-A.
Materials and methods

Cell isolation and culture
Specimens of proliferating IH were obtained from the Department of Plastic Surgery, Children's Hospital Boston, under a human subject protocol approved by the Committee on Clinical Investigation. The clinical diagnosis was confirmed in the Department of Pathology, Children's Hospital Boston. Informed consent was obtained for use of the IH specimens, according to the Declaration of Helsinki. HemSCs were isolated as described previously [4] . The derivation, sources, and culture conditions for the HemSCs and the other cells used in this study have been reported previously [4, 19, 20] . mRNA expression of NF-jB target genes in IH Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. A quantitative real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) was done with the following primers.
Immunohistochemical and immunofluorescence analyses
Human-specific CD31 (DakoCytomation) and uPAR immunostaining were performed as described [19, 21] . uPAR/ CD31 double immunofluorescence was done on cryosections and on HemSCs in vitro. Slides were fixed with acetone, blocked with 1% BSA and incubated with mouse anti-uPAR (American Diagnostica Inc., Stamford, CT, 1:100) over-night, followed by Alexa-Fluor 488-conjugated anti-mouse, and goat anti-human CD31 (Santa Cruz Biotechnology Inc.,Santa Cruz, CA) followed by biotinylated anti-goat and Streptavidin-Texas Red (1:200; Vector Laboratories, Burlingame CA).
Western blot for phosphorylated p65 and phosphorylated IjB
To test for dexamethasone effect on p65 phosphorylation, HemSCs were plated on 100 mm dishes and incubated with dexamethasone (200 nM) for 96 h. To test for the effect of Velcade on IkB phosphorylation cells were plated on 60 mm dishes and incubated with Velcade or dexamethasone for 24 or 72 h. Treated cells and control, untreated cells were lysed and 50 lg protein was separated by SDS-gel electrophoresis and transferred to a membrane. The membrane was blotted with anti-phosphorylated p65(Ser468) (rabbit, Cell Signaling, Beverly MA 1:1000), anti-phosphorylated-IjBa (Ser32/36) (mouse (clone 5A5) Cell Signaling or with anti-b actin (mouse, Sigma-Aldrich, St Louis, MO).
NF-jB DNA-Binding activity assay
Nuclear protein extracts were prepared using the NucBuster Protein Extraction Kit (Novagen, Madison, WI) according to the manufacturer's instructions. DNA-binding activity of NF-jB was assayed colorimetrically, utilizing the NoShift Transcription Factor Assay Kit and NoShift NF-jB (p65) reagents (both Novagen) according to the manufacturer's instructions.
Viability and proteosome activity assays Velcade (Bortezomib) was a kind gift from Dr. Alfred Goldberg, Department of Cell Biology, Harvard Medical School. Drug was dissolved in DMSO and aliquots were kept at -20°C. For proliferation assays, HemSCs and human bone marrow-derived mesenchymal stem cells (BM-MSCs) were plated at 4000cells/well in a 96-well plate. Twenty-four hours later, medium was replaced with EBM-2 containing Velcade at the indicated concentration. Cell viability was determined seventy-two hours later by CellTiter-Glo Ò (Promega, Madison, WI) according to the manufacturer's instructions.
For measuring the chymotrypsin-like peptidase activity of the 20S proteasome, HemSCs were plated at 10 4 cells/well at 12-well dishes. Twelve hours later medium was replaced with the indicated concentrations of Velcade in fresh media. After seventy-two hours, the cells were lysed with RIPA buffer and 20 lg of protein was added to each well of 96-well dark plate with LLVY buffer (Boston Biochem, Cambridge, MA #S-280). Fluorescence rate was measured by plate reader with kex 380 nm: 460 nm 378 30 cycles.
HemSCs VEGF quantitative RT-PCR and ELISA
A RT-qPCR assay was used to measure VEGF-A mRNA [22] . An enzyme-linked immunoassay (ELISA) was performed using Quantikine Human VEGF (R&D Systems, Inc., Minneapolis, MN).
Statistical analysis
Data was analyzed by Mann-Whitney. Differences were considered significant at P \ 0.05.
Results
MCP-1, IL-6 and uPAR are differentially expressed in proliferating versus involuting IH
As an indirect measure of NF-jB activity in proliferating IH, we analyzed nine IH tissues, four proliferative and five involuting specimens, for the mRNA expression of three NF-jB target genes: MCP-1, uPAR, and IL-6. Clinical data on the IH patients with IH is provided in Table 1 . RT-qPCR analyses revealed higher expression of all three genes in proliferating versus involuting IH (Fig. 1a-c) . The difference between the groups was statistically significant with p = 0.016, p = 0.03 and p = 0.016 for MCP-1, uPAR, and IL-6, respectively. CD31 expression analysis was done as a measure of the tissue endothelial content. As shown in Fig. 1d , proliferating IH had higher CD31 expression than involuting IH (average of 173.9 vs. 70.3, respectively). However, the differences did not reach significance (p = 0.09), indicating that the involuting tissues are still vascular. The differential expression of three NF-jB target genes in proliferating versus involuting IH suggested that NF-B activity may play a role in IH vasculogenesis.
uPAR is expressed by HemSCs and in proliferating IH MCP-1 has been reported to be differentially expressed in proliferating versus involuting IH [23] and IL-6 was downregulated following corticosteroid treatment in one patient [24] . In contrast, uPAR expression has not been reported in IH. Thus, we focused on testing uPAR expression in IH tissues and HemSCs. uPAR is a multidomain cell surface glycoprotein that has been implicated in cellular growth, metastasis, and angiogenesis in several solid and hematologic malignancies [25] [26] [27] . HemSCs expressed uPAR protein as demonstrated by immunofluorescence (Fig. 2a) and by Western blot (Fig. 2b) . We then tested whether uPAR is expressed at the protein level in IH tissue specimens. We found a strong cellular staining in almost every vessel of the proliferating IH (Fig. 2c) . In contrast, involuting IH expressed very little uPAR (Fig. 2c) . To better localize uPAR expressing cells within the proliferating IH, we performed double-label immunofluorescence. uPAR expression was noted at the periphery of the vascular channels. There was only occasional co-localization with the endothelial marker CD31 (Fig. 2d) .
Dexamethasone suppresses NF-jB activity of HemSCs
Our findings suggest increased NF-jB activity in proliferating versus involuting IH. We hypothesized that corticosteroids, the traditional pharmacological treatment for IH, work by suppressing this function, as this could account for reduced expression of VEGF-A, MCP-1, IL-6, uPAR and MMP-1 in HemSC treated with dexamethasone [5] . Thus, we tested the effect of dexamethasone on NF-jB activity of HemSCs. First, we analyzed the expression of the phosphorylated p65(S468) subunit of NF-jB. The p50 (NFKB1)/p65 (RELA) heterodimer is the most abundant form of NF-jB [28] . Phosphorylation of p65 by IKK at S468 occurs after TNF-a or IL-1b stimulation, mainly in the nucleus [29, 30] , and thus this form represents a good correlate of activated p65. As shown in Fig. 3a , dexamethasone (200 nM) down-regulated phosphorylated p65. Next, we directly assessed NF-jB DNA-complexing activity in nuclear extracts of HemSCs treated with dexamethasone by assaying the binding of NF-jB to oligonucleotides containing the consensus binding site [31, 32] . We found that dexamethasone suppressed NF-jB binding activity by 73% (Fig. 3b) . As a control, we used HemSCs treated with NEMO-binding domain (NBD) peptide or mutant NBD. NBD is a selective inhibitor of NF-jB activation [33, 34] . Treatment of HemSCs with NBD, but not with mutant NBD, decreased NF-jB binding activity (Fig. 3b) . To assess sequence-specific binding activity, nuclear extracts of untreated cells were incubated with NF-jB wild-type DNA, with or without either specific NFjB consensus binding motif or non-specific mutant NF-jB consensus-binding motif. Specific competitor DNA, but not the nonspecific binding motif, significantly reduced the binding activity, confirming sequence-specificity of the assay for NF-jB binding. HeLa cell nuclear extract provided a positive control for NF-jB binding activity. In summary, these results suggest that treatment of HemSCs with dexamethasone suppressed NF-jB activity.
Velcade (Bortezomib) inhibits HemSCs proteosome activity and impairs HemSCs viability
To study the role of NF-jB in HemSC survival and proangiogenic function, we used the selective proteosome inhibitor Velcade (Bortezomib) to block NF-jB activity. NF-jB is normally sequestered in the cytoplasm by the protein inhibitor of NF-jB (IjB). Velcade, by binding at high affinity to the proteasome, prevents IjB degradation. This allows IjB to accumulate in the cytoplasm and maintains NF-jB in its inactive state [35, 36] . We verified the activity of Velcade on HemSCs by testing its chymotrypsin-like peptidase inhibitory effect of the 20S proteasome. Velcade, at 1 and 5 nM inhibited proteosome activity in HemSCs by 22.3 and 56.3%, respectively (Fig. 4a ). Subsequently, we tested the effect of Velcade on HemSCs viability. Velcade induces killing of tumor cells by diverse mechanisms, among them is the inhibition of the NF-jB pathway [37] . Treatment of HemSCs with Velcade HemSCs were more sensitive to the cytotoxic effect of Velcade than BM-MSCs (Fig. 4b) . To verify that Velcade has an effect on NF-kB pathway in HemSCs, we analyzed the effect of Velcade on IjB phosphorylation. Velcade led to time-dependent increase in HemSC phosphorylated-IjB (p-IkB), similar to the effect of dexamethasone (Fig. 4c) .
Velcade down-regulates the expression of MCP-1, uPAR, MMP-1 and IL-6 in HemSCs
We identified MCP-1, uPAR, MMP-1 and IL-6 as proangiogenic cytokines secreted by HemSCs and HemEC and regulated by corticosteroids [5] . In order to investigate whether these cytokines are controlled by NF-jB in the specific cellular context of HemSCs, we tested the effect of
Velcade on their expression in HemSCs. Consistent with our previous finding [5] , dexamethasone led to a dosedependent inhibition of MCP-1, uPAR, MMP-1 and IL-6 expression (Supplemental Figure 1) . Similarly, by RT-qPCR, we found that Velcade down-regulated the expression of these cytokines in HemSCs (Fig. 5a-d ).
VEGF-A expression by HemSCs is regulated by NF-jB
VEGF-A has been shown to be required for formation of hemangioma-like vessels in the murine model [5] . Indeed, HemSCs secrete large amounts of VEGF-A, which is markedly suppressed by corticosteroids. We tested the effect of NF-jB inhibition on VEGF-A expression in HemSCs: Velcade treatment (5 nM) down-regulated VEGF-A mRNA expression (Fig. 6a) . Similar results were observed at the protein level by ELISA (Fig. 6B) . Velcade, being a proteosome inhibitor, could exert its effect on VEGF by mechanisms other than direct NF-jB activity inhibition. In order to verify that NF-jB inhibition is involved, we used the specific NF-jB inhibitor 6-Amino-4-(4-phenoxyphenylethylamino) quinazoline (QNZ) [38] . Similar to the effect of Velcade, QNZ suppressed VEGF-A in HemSCs at both the mRNA (Fig. 6c ) and the protein (Fig. 6d) levels. In sum, these findings suggest that VEGF expression in HemSCs is regulated by NF-jB. 
Discussion
Our results indicate that NF-jB target genes are overexpressed in the proliferating versus the involuting phase of IH. In addition we show that corticosteroids suppress NF-jB activity in HemSCs and that this suppression leads to down-regulation of the pro-angiogenic cytokines MCP-1, uPAR, MMP-1 and IL-6. Moreover, we demonstrate that VEGF-A, a critical factor in IH, is regulated by NF-jB activity.
We found over-expression of MCP-1, uPAR and IL-6 in proliferating versus involuting IH. VEGF-A and urokinase plasminogen activator (uPA) are also NF-jB target genes previously reported to be differentially expressed [5, 39] . Also, several genes that activate NF-jB have been shown to be over-expressed in proliferating versus involuting IH. Among them are: avb3 and avb1 integrins [40] [41] [42] ; Tumor necrosis factor (ligand) superfamily member 10 (TRAIL) [43, 44] ; VE-Cadherin [40, 45] ; Platelet-derived growth factor receptor b (PDGFR b) [40, 46] . These findings suggest a role for the NF-jB system in the pathogenesis of IH. Further studies that employ direct activation or silencing of NF-jB in vivo are essential in order to establish a causative role for this signaling pathway in IH.
uPAR was found to be differentially expressed in proliferating versus involuting IH and to be a target of dexamethasone in HemSCs. The one involuting IH specimen that had detectable uPAR was in the early involuting phase, taken from a 14 month old infant. Our observation suggests a role for uPAR in the response to corticosteroids, as well as in natural involution. uPAR is a glycosylphosphatidylinositol anchored glycoprotein that is expressed by many tissues, especially during physiological and pathological tissue remodeling processes [26, 47] . It has been reported to regulate cell adhesion, migration, proliferation, survival, and angiogenesis, through interaction with an array of proteins, including extracellular matrix molecules, cell adhesion receptors, G-protein coupled receptors, and tyrosine kinase receptors [26, 47] . The uPAR ligand, the serine protease urokinase plasminogen activator (uPA), was shown to be expressed in both proliferating and involuting IH [39] . Future knockdown or over-expression studies will be required to shed light on the function of uPAR in the life cycle of IH.
Dexamethasone suppressed NF-jB activity in HemSCs. Glucocorticoid effects are mediated through the intracellular glucocorticoid receptor (GR), which binds cognate ligands and regulates target gene expression positively or negatively. Distinct mechanisms are probably responsible for GR regulation of NF-jB activities [48] . First, a physical interaction between NF-jB subunits and GR, similar to that shown for AP-1, has been reported [49] . Second, glucocorticoids have been demonstrated to induce transcription of the NF-jB inhibitor, IjBa [50] . Finally, it has also been demonstrated that both NF-jB and GR can compete for interactions with coactivators, such as p300 and CREBbinding protein (CBP), which are present in limited amounts [51, 52] . The occurrence and relative role of each mechanism seems to depend on both cellular and promoter contexts. Thus, it is of interest to further delineate the critical mechanisms responsible for the suppression of proangiogenic factors in HemSCs.
We have shown by different lines of evidence that the expression VEGF-A, a critical growth factor for IH vasculogenesis, is regulated by NF-jB in HemSCs. Our observations are in agreement with reports demonstrating a similar control process in other cells [53] [54] [55] [56] . The molecular mechanisms leading to VEGF transcriptional control by NF-jB are largely elusive. A recent report demonstrated a critical role for NF-jB-induced JunB in VEGF regulation and tumor angiogenesis [57] .
In summary, our findings of NF-jB target gene expression in IH and NF-jB regulation of VEGF-A expression by IH-derived stem cells may point to a role of this system in the IH pathogenesis. In an era of newly emerging, novel NF-jB -targeting drugs [58] , these insights may lead to a new pharmacological therapy for IH. 
